Funding
Profluent Raises $106M to Accelerate Frontier AI Models for Programmable Biology, Backed by Jeff Bezos
Profluent; AI biotech; protein design; programmable biology; Jeff Bezos; Altimeter Capital; $106M funding; Bezos Expeditions; CRISPR; biologics; Protein Atlas; synthetic biology; drug development
Arena BioWorks Shuts Down After Investors Withdraw Support for Bold Biotech Model
Arena BioWorks; biotech shutdown; policy uncertainty; funding environment; biomedical research; $500 million funding; layoffs; biotech industry; investor concerns
Jennifer Doudna’s Azalea Therapeutics Launches with $82M to Advance In Vivo CAR-T Using Novel CRISPR Delivery Technology
Jennifer Doudna; Azalea Therapeutics; CRISPR; in vivo CAR-T; gene editing; EDV technology; cancer therapy; autoimmune disease; Series A funding; B-cell malignancies
Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs
Zag Bio; Tregs; regulatory T cells; autoimmune diseases; thymus-targeted therapy; Series A funding; immune tolerance; Type 1 diabetes; AbbVie; Regeneron; Sanofi
Apptronik Raises $350 Million Series A to Scale AI Humanoid Robot Production
Apptronik; Series A funding; AI humanoid robots; Apollo robot; venture capital; robotics
Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale
Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding
Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment
biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding
Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug
Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding
Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates
Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing
Lila Sciences Raises $235M to Expand AI Science Factories
Lila Sciences; AI Science Factories; Autonomous Research; Biotechnology; Series A Funding